利培酮合并安脑丸治疗精神分裂症临床疗效观察  

Risperdal merger An Nao Wan for schizophrenia clinical curative effect observation

作　　者：张燕[1] 刘飞虎[1] 师建国[1] 张曼[1] 

机构地区：[1]陕西省西安市精神卫生中心,陕西西安710061

出　　处：《中国民族民间医药》2012年第22期46-48,共3页Chinese Journal of Ethnomedicine and Ethnopharmacy

基　　金：陕西省科技计划项目(2011KJXX65)

摘　　要：目的:评价利培酮合并安脑丸治疗精神分裂症的临床疗效。方法:筛选本市精神卫生中心2012年上半年住院的精神分裂症患者,其中单独给予利培酮和合并安脑丸给予利培酮治疗周期28天以上患者作为临床观察对象。以症状量表(PANSS)评定药物疗效,以副反应量表(TESS)评定不良反应。同时通过收集患者相关临床指标检测结果与日常病历记录信息详细记录不良反应。结果:筛选的427例患者中有50例符合条件,其中利培酮合并安脑丸治疗的11例,单独使用利培酮治疗的39例。利培酮单用与利培酮合并安脑丸治疗2周前后的症状量表评分都有显著下降(P<0.01)。利培酮单独治疗患者的不良反应发生率达53.8%,其中催乳素分泌增加达7例。而利培酮合并安脑丸治疗的患者不良反应的发生率仅为27.3%,出现催乳素分泌增加的只有1例。结论:利培酮合并安脑丸可以显著提高利培酮的治疗效果,缩短症状恢复时间,预防精神病药物的不良反应发生,同时也提高了用药安全性和病人依从性。Objective： to evaluate the clinical curative effect of risperdal merger An Nao Wan for schizophrenia.Methods： screening a mental health center in the first half of 2012 hospitalized patients with schizophrenia,which alone give risperdal or merger An Nao Wan give risperdal with 28 days treatment cycle,were as a clinical observation objects.Efficacy was assessed using symptoms scale（PANSS）,evaluation of adverse reactions was with side effects scale（TESS）.And through collecting the clinical data,related testing results,the daily detailed medical records to record adverse reactions.Results： 50 cases of screened 427 patients meet the conditions,including 11 cases with risperdal merger An Nao Wan,and 39 cases only used risperdal.All of 50 cases after two weeks treatment,the symptoms were down significantly（P 0.01）.The adverse reactions rate of patients only with Risperdal was 53.8%,of patients with risperidone merger An Nao Wan was only 27.3%.Conclusion： risperdal merger An Nao Wan can improve the therapeutic effect of risperidone,short the recovery time of Schizophrenia,prevent the adverse reaction of psychotic drug,also improve the safety and patient drug compliance.

关 键 词：安脑丸 利培酮 中药 精神分裂症 催乳素 

分 类 号：R749.3[医药卫生—神经病学与精神病学]